⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of OnKure Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
OnKure Therapeutics, Inc.
↗Boulder, Colorado, USA
OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers and vascular anomalies. The company utilizes a structure-based drug design platform to develop small-molecule therapies aimed at optimizing efficacy and tolerability for patients underserved by existing treatments.
Following a reverse merger with Reneo Pharmaceuticals in October 2024, the company operates as a publicly traded entity on the NASDAQ. OnKure is primarily focused on advancing its PI3Kα pan-mutant selective inhibitor portfolio, with its lead program, OKI-219, currently undergoing clinical evaluation.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$150M
Investors:Access Biotechnology, BVF Partners LP, RA Capital Management, Foresite Capital, Vivo Capital, Acorn Bioventures
STOCK
Exchange:NASDAQ
Ticker:OKUR
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Nicholas A. Saccomano - CEO
Rogan Nunn - General Counsel and Secretary
Scientific Founders:Xuedong Liu
Board Members:Liam Ratcliffe, R. Michael Carruthers, Mike Grey, Valerie Jansen, Isaac Manke, Ed Mathers, Andrew Philips
LINKS
Website:onkure.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with OnKure Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.